Accessibility Menu
 
Coherus Oncology logo

Coherus Oncology

(NASDAQ) CHRS

Current Price$1.80
Market Cap$268.34M
Since IPO (2014)-86%
5 Year-88%
1 Year+74%
1 Month+9%

Coherus Oncology Financials at a Glance

Market Cap

$268.34M

Revenue (TTM)

$42.17M

Net Income (TTM)

$168.02M

EPS (TTM)

$-1.46

P/E Ratio

-1.19

Dividend

$0.00

Beta (Volatility)

1.66 (High)

Price

$1.80

Volume

218,382.021

Open

$1.74

Previous Close

$1.74

Daily Range

$1.74 - $1.80

52-Week Range

$0.71 - $2.62

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Coherus Oncology

Industry

Biotechnology

Employees

147

CEO

Denny M. Lanfear, MBA

Headquarters

Redwood City, CA 94065, US

CHRS Financials

Key Financial Metrics (TTM)

Gross Margin

67%

Operating Margin

-4%

Net Income Margin

4%

Return on Equity

-861%

Return on Capital

-2%

Return on Assets

65%

Earnings Yield

-84.03%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$268.34M

Shares Outstanding

154.22M

Volume

218.38K

Avg. Volume

1.48M

Financials (TTM)

Gross Profit

$28.36M

Operating Income

$181.13M

EBITDA

$170.20M

Operating Cash Flow

$138.51M

Capital Expenditure

$0.00

Free Cash Flow

$138.51M

Cash & ST Invst.

$172.13M

Total Debt

$40.34M

Coherus Oncology Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$12.75M

-76.5%

Gross Profit

$8.70M

-57.1%

Gross Margin

68.27%

N/A

Market Cap

$268.34M

N/A

Market Cap/Employee

$1.18M

N/A

Employees

228

N/A

Net Income

$37.64M

+25.7%

EBITDA

$43.20M

+2.5%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$131.79M

+191.6%

Accounts Receivable

$18.42M

-84.9%

Inventory

$3.17M

-95.5%

Long Term Debt

$38.51M

-85.6%

Short Term Debt

$1.83M

+8.1%

Return on Assets

65.04%

N/A

Return on Invested Capital

-1.56%

N/A

Free Cash Flow

$19.72M

-168.9%

Operating Cash Flow

$19.72M

-168.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CDXSCodexis, Inc.
$2.83+0.53%
CCCCC4 Therapeutics, Inc.
$2.69+4.88%
TARAProtara Therapeutics, Inc.
$5.19+0.46%
IVVDInvivyd, Inc.
$1.41+3.31%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$12.54+0.01%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.59+0.09%
SOFISoFi Technologies
$16.17+0.04%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$12.36+0.04%

Questions About CHRS

What is the current price of Coherus Oncology?

Coherus Oncology is trading at $1.80 per share.

What is the 52-week range for Coherus Oncology?

Over the past 52 weeks, Coherus Oncology has traded between $0.71 and $2.62.

How much debt does Coherus Oncology have?

As of the most recent reporting period, Coherus Oncology reported total debt of $54.36M.

How much cash does Coherus Oncology have on hand?

Coherus Oncology reported $88.88M in cash and cash equivalents in its most recent financial results.

What is Coherus Oncology’s dividend yield?

Coherus Oncology does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.